VivoSim Labs (NASDAQ:VIVS – Get Free Report) and MindWalk (NASDAQ:HYFT – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.
Earnings and Valuation
This table compares VivoSim Labs and MindWalk”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VivoSim Labs | $130,000.00 | 8.92 | -$13.84 million | ($5.36) | -0.06 |
| MindWalk | $11.24 million | 5.44 | -$10.11 million | ($0.22) | -5.95 |
Analyst Recommendations
This is a summary of current recommendations for VivoSim Labs and MindWalk, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
| MindWalk | 2 | 0 | 2 | 1 | 2.40 |
MindWalk has a consensus price target of $5.00, indicating a potential upside of 281.68%. Given MindWalk’s stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than VivoSim Labs.
Insider & Institutional Ownership
8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares VivoSim Labs and MindWalk’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VivoSim Labs | -10,567.17% | -277.62% | -153.77% |
| MindWalk | -89.65% | -92.61% | -54.15% |
Volatility and Risk
VivoSim Labs has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Summary
MindWalk beats VivoSim Labs on 11 of the 15 factors compared between the two stocks.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
